Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050216 · ClinicalTrials.gov registry record · Phase 2
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03050216 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 8 participants.
The verdict
NCT03050216, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a multi-institutional Simon's optimal two-stage phase II trial of CD3/CD19 depleted, ALT-803 activated, haploidentical donor NK cells and subcutaneous ALT-803 given after lymphodepleting chemotherapy (CY/FLU) for the treatment of refractory or released acute myelogenous leukemia (AML).
Interventions
- BIOLOGICAL ALT-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03050216
The ClinicalTrials.gov registry entry for NCT03050216 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALT-803 is the first listed.
NCT03050216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03050216 about?
NCT03050216 is a clinical study titled "QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML". This is a multi-institutional Simon's optimal two-stage phase II trial of CD3/CD19 depleted, ALT-803 activated, haploidentical donor NK cells and subcutaneous ALT-803 given after lymphodepleting chemotherapy (CY/FLU) for the treatment of refractory or released acute myelogenous leukemia (AML).
What is the current status of trial NCT03050216?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2017-05-16. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT03050216?
The interventions under investigation include: ALT-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03050216?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.